Latest Information Update: 03 Dec 2002
At a glance
- Originator Bioglan Pharma [CEASED]
- Class Analgesics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 03 Dec 2002 Discontinued - Preclinical for Pain in United Kingdom (unspecified route)
- 18 Jun 2001 Preclinical development for Pain in United Kingdom (Unknown route)